Navigation Links
Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimer's Disease
Date:3/3/2008

EMERYVILLE and NOVATO, Calif., March 3 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (Nasdaq: NTII) and the Buck Institute for Age Research (Buck) announced today they have entered into a collaboration and exclusive license agreement to develop a novel therapy for Alzheimer's Disease (AD). Under the terms of the agreement Neurobiological Technologies will exclusively license certain patent rights related to a naturally occurring protein that has been shown in animals to reverse the symptoms of Alzheimer's disease.

AD is a neurodegenerative disease that, in its most common form, occurs in people over 65 years old and is the most common cause of dementia afflicting 24 million people worldwide.

AD Research at the Buck Institute focuses on signal transduction pathways that may explain all of the different, yet seemingly opposed theories of AD, namely that AD is caused by either an overabundance of amyloid-B (AB) peptide, or neurofibrillary tangles that build up inside the nerve cells. Current studies at the Buck are focused on a naturally occurring protein that has been shown in both cell culture and mice to inhibit the production of amyloid-B (AB) peptides while simultaneously facilitating the growth and preservation of nerve fibers in the brain.

As part of this agreement, Neurobiological Technologies has agreed to fund a joint research collaboration with the Buck relating to the Alzheimer's drug development for up to three years. Research funding for the initial year under the Agreement will total $1.2 million. In consideration for the license, Neurobiological Technologies will pay upfront license fees totaling $175,000 over a three-year period.

"The partnership with the Buck Institute has the potential to expand our pipeline of product candidates in central nervous system disorders," said Paul E. Freiman, President and CEO of Neurobiological Technologies. "We look forward to applying our resources and expertise in drug development to this partnership and working to bring this important AD research from the lab to the clinic."

Neurobiological Technologies has been collaborating with Buck since December 2007 to develop a new drug for the treatment of Huntington's disease involving fibroblast growth factor-2 (FGF-2), a naturally occurring protein that has been studied extensively for its neuroprotective properties. This agreement is the second collaboration between Neurobiological Technologies and Buck focused on central nervous system conditions.

"With these resources and the support from Neurobiological Technologies, we are well positioned to realize our shared goal of developing drugs to bring new hope to patients suffering from AD," said Remy Gross, Buck Institute Director of Business Development. "We look forward to this second important research and development partnership for underserved CNS disorders that affect an increasing number of people worldwide."

About the Buck Institute

The Buck Institute is an independent non-profit organization dedicated to extending the healthspan, the healthy years of each individual's life. The National Institute of Aging designated the Buck a Nathan Shock Center of Excellence in the Biology of Aging, one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating age-related diseases such as Alzheimer's and Parkinson's disease, cancer, stroke, and arthritis. Collaborative research at the Institute is supported by genomics, proteomics and bioinformatics technology. For more information: http://www.buckinstitute.org.

About Neurobiological Technologies

Neurobiological Technologies, Inc, (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate in phase 3 clinical testing is Viprinex(TM) (ancrod), a novel agent with multiple mechanisms that is specifically designed to expand the treatment window for treating acute ischemic stroke, one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. Its pipeline includes other drug candidates in early-stage development, including a first-of-its-kind drug for the treatment of Alzheimer's disease.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including risks relating to the acquisition of new product candidates and our levels of future expenditures and capital resources, as well as other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements.


'/>"/>
SOURCE Neurobiological Technologies, Inc.; Buck Institute for AgeResearch
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Emisphere Technologies, Inc. Announces 2007 Third Quarter Financial Results
2. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
3. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
4. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
5. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
6. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
7. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. American Legion Anticipates Institute of Medicine Report on Gulf War Veterans
10. SAIC Awarded Malaria Vaccine Production Support Contract Extension by the National Institute of Allergy and Infectious Diseases
11. American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 28, 2017 , ... Accreditation Commission for Health Care (ACHC) ... America (HCAOA). This agreement allows HCAOA members to receive special pricing on ACHC’s ... Accreditation University (AU) educational resources that help prepare HCAOA members for ACHC Accreditation. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... Getting enough sleep affects much more than ... (NSF), going just 19 hours without sleep can compromise motor reaction time, which can increase ... and Amica Insurance is sharing the following tips from the NSF to help you sleep ...
(Date:4/28/2017)... ... April 28, 2017 , ... Datta Endoscopic Back Surgery ... the revolutionary endoscopic practice under Dr. Datta. Patel is a Board Certified Anesthesiologist, ... patented, revolutionary eDiscSculpt Technique created and used by Datta Endoscopic is unlike traditional ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions ... Grove Foundation implement a Microsoft Dynamics GP solution that integrates to their PointClickCare ... that specializes in long-term care, Brooke Grove now has the capability to achieve ...
Breaking Medicine News(10 mins):